Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

BACKGROUND: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC. CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation e...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Gynecol Oncol Rep
Asıl Yazarlar: Han, Chanhee, Bellone, Stefania, Zammataro, Luca, Schwartz, Peter E., Santin, Alessandro D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2018
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6014583/
https://ncbi.nlm.nih.gov/pubmed/29946554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2018.05.011
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller